v3.25.1
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Total
Series A Common Stock
Series B Common Stock
Conversion of Common Stock Upon Shareholder Election and Vesting of Certain Equity Awards
Common Stock
Series A Common Stock
Common Stock
Series B Common Stock
Common Stock
Conversion of Common Stock Upon Shareholder Election and Vesting of Certain Equity Awards
Series A Common Stock
Common Stock
Conversion of Common Stock Upon Shareholder Election and Vesting of Certain Equity Awards
Series B Common Stock
Additional Paid-In Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023         40,841,834 218,524,009        
Beginning balance at Dec. 31, 2023 $ 914,777       $ 41 $ 219     $ 1,713,560 $ (799,043)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Issuance of common stock upon exercise of common stock options (in shares)           3,715,082        
Issuance of common stock upon exercise of common stock options 3,564         $ 3     3,561  
Issuance of common stock upon vesting of restricted stock units (in shares)         35,673 973,988        
Issuance of common stock upon vesting of restricted stock units 0         $ 1     (1)  
Issuance of common stock upon exercise of collaboration agreement warrants (in shares)           344,382        
Issuance of common stock upon exercise of collaboration agreement warrants 4               4  
Vested warrants related to collaboration agreement 8,100               8,100  
Stock-based compensation expense 35,754               35,754  
Tax withholdings on settlement of stock-based awards (in shares)         (15,168) (384,092)        
Tax withholdings on settlement of stock-based awards (11,865)               (11,865)  
Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards (in shares)             29,203,494 (29,203,494)    
Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards       $ 0     $ 29 $ (29)    
Net loss (12,882)                 (12,882)
Ending balance (in shares) at Mar. 31, 2024         70,065,833 193,969,875        
Ending balance at Mar. 31, 2024 937,452       $ 70 $ 194     1,749,113 (811,925)
Beginning balance (in shares) at Dec. 31, 2024   88,956,301 183,801,332   88,956,301 183,801,332        
Beginning balance at Dec. 31, 2024 1,033,987       $ 89 $ 184     1,878,899 (845,185)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Issuance of common stock upon exercise of common stock options (in shares)           920,727        
Issuance of common stock upon exercise of common stock options 877         $ 1     876  
Issuance of common stock upon vesting of restricted stock units (in shares)         885,380 742,420        
Issuance of common stock upon vesting of restricted stock units (1)       $ 1 $ 1     (3)  
Issuance of common stock upon exercise of collaboration agreement warrants (in shares)           344,382        
Issuance of common stock upon exercise of collaboration agreement warrants 3               3  
Vested warrants related to collaboration agreement 8,100               8,100  
Stock-based compensation expense 39,434               39,434  
Tax withholdings on settlement of stock-based awards (in shares)         (47,175) (45,997)        
Tax withholdings on settlement of stock-based awards (4,379)               (4,379)  
Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards (in shares)             4,779,530 (4,779,530)    
Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards       $ 0     $ 5 $ (5)    
Net loss (14,089)                 (14,089)
Ending balance (in shares) at Mar. 31, 2025   94,574,036 180,983,334   94,574,036 180,983,334        
Ending balance at Mar. 31, 2025 $ 1,063,932       $ 95 $ 181     $ 1,922,930 $ (859,274)